NIVF vs TMHC

For growth investors, NewGenIvf Group Limited (NIVF) is the stronger pick with 5.

8% revenue growth year-over-year, versus -0. 6% for Taylor Morrison Home Corporation (TMHC). Taylor Morrison Home Corporation (TMHC) offers the better valuation at 7. 7x trailing P/E (11. 2x forward), making it the more compelling value choice. Analysts rate Taylor Morrison Home Corporation (TMHC) a "Buy" — based on 30 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Taylor Morrison Home Corporation (TMHC) delivered a total return of +85.

7%, compared to -100. 0% for NewGenIvf Group Limited (NIVF). Over 10 years, the gap is even starker: TMHC returned +321. 2% versus NIVF's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Taylor Morrison Home Corporation (TMHC) is the lower-risk stock at 0.

92β versus NewGenIvf Group Limited's 1. 96β — meaning NIVF is approximately 113% more volatile than TMHC relative to the S&P 500.

By revenue growth (latest reported year), NewGenIvf Group Limited (NIVF) is pulling ahead at 5.

8% versus -0. 6% for Taylor Morrison Home Corporation (TMHC). On earnings-per-share growth, the picture is similar: Taylor Morrison Home Corporation grew EPS -6. 0% year-over-year, compared to -279. 4% for NewGenIvf Group Limited. Over a 3-year CAGR, NIVF leads at 9. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Taylor Morrison Home Corporation (TMHC) is the more profitable company, earning 9.

6% net margin versus -9. 7% for NewGenIvf Group Limited — meaning it keeps 9. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TMHC leads at 14. 0% versus -21. 4% for NIVF. At the gross margin level — before operating expenses — NIVF leads at 33. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Taylor Morrison Home Corporation (TMHC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

92), +321. 2% 10Y return). NewGenIvf Group Limited (NIVF) carries a higher beta of 1. 96 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TMHC: +321. 2%, NIVF: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NIVF (Healthcare) and TMHC (Consumer Cyclical)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NIVF is a small-cap quality compounder stock; TMHC is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.